These data show that, in this model of type 1 diabetes, TLR4 blockade impairs the activation of CD4+ T lymphocytes and the production and secretion of pro-inflammatory cytokines, as observed in NOD mice. The gene discussed is CD4; the disease is type 1 diabetes mellitus.